NASDAQ: ELDN - Eledon Pharmaceuticals, Inc.

Rentabilité sur six mois: +58.6%
Secteur: Healthcare

Calendrier des promotions Eledon Pharmaceuticals, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc.

Plus de détails
and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Выручка 0.00012
EBITDA -0.0121
P/BV 0.7605
EV/EBITDA 0.1046
P/S 186.27
Цена ао 2.12
ISIN US28617K1016
Число акций ао 0.02462 млрд
Сайт https://eledon.com
Валюта usd
IPO date 2014-09-17
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Changement de prix par jour: +7.27% (2.75)
Changement de prix par semaine: +11.74% (2.64)
Changement de prix par mois: +13.9% (2.59)
Changement de prix sur 3 mois: +11.32% (2.65)
Changement de prix sur six mois: +58.6% (1.86)
Changement de prix par an: +103.45% (1.45)
Evolution du prix sur 3 ans: -50.34% (5.94)
Evolution du prix sur 5 ans: +278.21% (0.78)
Evolution des prix depuis le début de l'année: +145.83% (1.2)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 0.4515 10
P/E 0 0
EV/EBITDA -0.7845 0
Total: 3.75

Efficacité

Nom Signification Grade
ROA, % -32.03 0
ROE, % -48.34 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.009 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 252.28 10
Rentabilité EPS, % -94.55 0
Total: 6
Plus de détails

Établissements Volume Partager, %
BVF Inc. 4326710 17.88
Armistice Capital, LLC 1824000 7.54
Vanguard Group Inc 674520 2.79
Woodline Partners LP 603993 2.5
Ensign Peak Advisors, Inc 443001 1.83
CM Management, LLC 234803 0.97
Geode Capital Management, LLC 176039 0.73
Royal Bank of Canada 158207 0.65
Renaissance Technologies, LLC 61973 0.26
JMAC Enterprises LLC 58041 0.24

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
Dimensional U.S. Core Equity 2 ETF 0.00015 37.528779739064 1.47098
Dimensional U.S. Targeted Value ETF 0.00028 32.980877390326 1.93487
iShares Micro-Cap ETF 0.02284 43.316995205115 1.54048



Superviseur Titre d'emploi Paiement Année de naissance
Dr. David-Alexandre C. Gros M.D., Ph.D. CEO & Non Independent Director 807.96k 1972 (52 année)
Dr. Steven N. Perrin Ph.D. President, Chief Scientific Officer & Non Independent Director 603.9k 1966 (58 années)
Mr. Paul Sean Little Chief Financial Officer 611.71k 1965 (59 années)
Mr. John Herberger Vice President of Technical Operations N/A
Mr. Bryan E. Smith J.D. General Counsel, Corporate Secretary & Chief Compliance Officer 377.14k 1980 (44 année)
Dr. David Hovland Ph.D. Chief Regulatory Officer N/A
Dr. Eliezer Katz F.A.C.S., FACS, M.D. Chief Medical Officer N/A

Adresse: United States, Irvine. CA, 19900 MacArthur Boulevard - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://eledon.com